Table 3.
SB-PRE | SB-POST |
p-Value Z1 or F2 rc1 or 2 |
PLA-PRE | PLA-POST |
p-Value Z1 or F2 rc1 or 2 |
Δ SB PRE-POST |
Δ PLA PRE-POST |
p-Value Z1 or F2 rc1 or 2 |
|
---|---|---|---|---|---|---|---|---|---|
Time (s) | 919 ± 42 | 912 ± 27 | 0.0501 | 919 ± 33 | 920 ± 31 | 0.0882 | −6.5 ± 53.1 | 0.5 ± 32.6 | 0.6381 |
1.9561 | 3.5762 | 0.4711 | |||||||
0.5901 | 0.2632 | 0.1361 | |||||||
HRmax (bpm) | 179 ± 5 | 179 ± 7 | 0.7561 | 179 ± 9 | 179 ± 7 | 0.2512 | −0.3 ± 3.9 | −0.7 ± 9.4 | 0.4241 |
0.3111 | 1.4852 | 0.8001 | |||||||
0.0941 | 0.1292 | 0.2411 | |||||||
HRaverage (bpm) | 160 ± 6 | 159 ± 7 | 0.2661 | 159 ± 7 | 160 ± 7 | 0.6442 | −1.2 ± 4.7 | 1.0 ± 4.7 | 0.9632 |
1.1111 | 0.2272 | 0.0022 | |||||||
0.3351 | 0.0222 | 0.0002 |
1Data analyzed by Wilcoxon signed-rank test; effect size expressed as rank correlation coefficient (rc). 2Data analyzed by two-way ANOVA with repeated measurements; effect size expressed as partial eta-squared (). Abbreviations: HRaverage – average heart rate, HRmax – maximal heart rate, PLA-PRE – before placebo treatment, PLA-POST – after placebo treatment, SB-PRE – before sodium bicarbonate supplementation, SB-POST – after sodium bicarbonate supplementation